Compare NFE & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | CABA |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 319.6M |
| IPO Year | 2018 | 2019 |
| Metric | NFE | CABA |
|---|---|---|
| Price | $0.59 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.70 | ★ $13.43 |
| AVG Volume (30 Days) | ★ 20.0M | 1.7M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $89.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.99 |
| 52 Week High | $7.92 | $3.78 |
| Indicator | NFE | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 25.05 | 45.35 |
| Support Level | N/A | $2.11 |
| Resistance Level | $1.38 | $3.34 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 3.72 | 36.15 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.